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Abstract
The 1,2,4-thiadiazole moiety is an important component of several biologically 
active compounds, and varying substituents on this aromatic ring is one of the 
possible methods to develop novel thiadiazole-based drugs for medicine. A key 
building block to this end, namely 3,5-diiodo-1,2,4-thiadiazole (1), has been syn-
thesized and characterized in this work for the first time. 1 has exhibited high selec-
tivity for the replacement of iodine atom at position C5 (carbon next to sulfur) in 
Sonogashira-type cross-coupling reactions with phenylacetylene. Therefore, 3-iodo-
5-(phenylethynyl)-1,2,4-thiadiazole (4) or 3,5-bis(phenylethynyl)-1,2,4-thiadiazole 
(5) could be synthesized selectively depending on reaction conditions. All three 
novel molecules have been characterized by NMR, IR, Raman, mass, and UV spec-
troscopies, and their solid phase structures have been determined by single-crystal 
X-ray diffraction. 1 is expected to be a key starting material for producing thiadia-
zole-based therapeutic agents using cross-coupling reactions.
Keywords 1,2,4-Thiadiazoles · Crystal structure · Spectroscopy · Cross-coupling 
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Introduction
Heterocyclic compounds have wide-ranging biological activities, and the 
1,2,4-thiadiazole substructure has received increasing attention due to its poten-
tial application as insecticides, herbicides, fungicides, and therapeutic agents 
[1–6]. Ceftaroline fosamil and ceftobiprole medocaril, for example, are recently 
approved fifth-generation cephalosporin antibiotics [1], and 1,2,4-thiadiazole 
derivatives have been shown to exhibit anticancer, anti-viral, neuroprotective, and 
cardioprotective activities [5–7]. 1,2,4-Thiadiazole rings are usually constructed 
by intra- or inter-molecular cyclization strategies [6–8] during the synthesis of 
larger biologically active molecules. Another efficient route to produce molecules 
incorporating the thiadiazole unit could be the replacement of substituent atoms 
or groups at the 3- and 5-positions of the 1,2,4-thiadiazole moiety. This is espe-
cially important for the covalent amalgamation of 1,2,4-thiadiazole with reason-
ably selected fragments of different biologically active agents, which could lead 
to compounds with improved activity and selectivity due to synergistic effects 
[9, 10]. Therefore, the development of synthetic protocols to this end is of cru-
cial importance. The direct linking of the thiadiazole frame to selected frag-
ments using cross-coupling reactions is expected to be a promising route to novel 
1,2,4-thiadiazole derivatives. Key building blocks for these coupling reactions, 
namely 3,5-diiodo-1,2,4-thiadiazole (1) and 3,5-dibromo-1,2,4-thiadiazole (2), 
however, are not known to date. Therefore, the original aim of the present work 
was to find routes to these molecules and to test their applicability in cross-cou-
pling reactions.
In this paper, we report on the first synthesis and structural analysis of 1, as 
well as on its cross-coupling reactions with phenylacetylene. The structure of 1 
and its coupled products is confirmed by spectroscopy and single-crystal X-ray 
diffraction. This coupling reaction is the key model reaction for linking potential 




All reactions in this work were carried out under an inert nitrogen atmosphere 
using standard techniques. Chemicals used were reagent grade from com-
mercial sources (Sigma-Aldrich, Fluka) and used without further purification. 
3,5-Diamino-1,2,4-thiadiazole (3) was prepared according to a previously pub-
lished method [11].
NMR spectra of synthesized compounds were obtained on Bruker Avance 
250  MHz and Bruker DRX-500  MHz spectrometers using the deuterium signal 
of the solvent as the lock and tetramethylsilane (TMS) as the internal standard. 
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The assignment of all 1H- and 13C-NMR data necessary for exact structural elu-
cidation of the compounds was based on the cross-peak correlations discernible 
in 2D-HSQC and HMBC spectra obtained by standard Bruker pulse programs. 
Infrared (IR) and Raman spectra were recorded on Bruker Alpha and Bruker IFS 
55 Fourier transform spectrometers, respectively, using a resolution of 2  cm−1. 
Spectrophotometric measurements were done using a PerkinElmer UV/Vis 
Lambda 35 spectrometer applying a slit width of 1 nm and acetonitrile as solvent. 
Mass spectroscopic measurements were taken using an Esquire 3000+ (Bruker) 
ion trap mass spectrometer or an Agilent 5973 Mass spectrometer of a GC–MS 
instrument. Exact mass measurement was taken on a high-resolution Q-Exactive 
Focus hybrid quadrupole-orbitrap mass spectrometer (Thermo Fisher Scientific) 
equipped with heated electrospray ionization source. Samples were dissolved in 
acetonitrile–water 1:1 (V/V) solvent mixture containing 0.1% (V/V) acetic acid.
Synthesis of 3,5‑diiodo‑1,2,4‑thiadiazole, 1
Tert-butyl nitrite (5 ml, 4.34 g, 43 mmol) was added slowly to CuI (6 g, 31 mmol) 
in 45 ml of dry  CH3CN at room temperature under nitrogen atmosphere. The reac-
tion flask was then heated up using a 70 °C water bath. 3,5-Diamino-1,2,4-thiadi-
azole (1.5 g, 13 mmol) dissolved in 20 ml of anhydrous DMF was then added to 
the mixture drop-wise, and the reaction medium was stirred at 70  °C for 30 min. 
The reaction was quenched with 220 ml of cold water, and products were extracted 
with cyclohexane (3 × 50 ml). The combined organic layer was washed with water 
(2 × 50 ml) and dried over anhydrous  MgSO4. Filtration and concentration of this 
latter in vacuo provided a powder-like white solid product (yield: 14%). M.p.: 
129–131  °C; NMR  (CDCl3, r.t.): 13C-NMR (62.5  MHz): 118.7 (C3), 126.9 (C5) 
ppm; MS: 337.8  [M]+, 184.9  [ICNS]+, 126.9 m/z  [I]+; UV–Vis (λmax, acetonitrile): 
237 (ε = 527 m2 mol−1), 261 nm.
Measured spectroscopic data of 3,5‑diamino‑1,2,4‑thiadiazole, 3
NMR (DMSO-d6, r.t.): 1H-NMR (250 MHz): 5.91 (s, 2H), 7.53 (s, 2H) ppm; 13C-
NMR (62.5 MHz): 166.7 (C3), 181.6 (C5) ppm. MS: 117.0 m/z [M + 1]+; UV–Vis 
(λmax, acetonitrile): 256 (ε = 406 m2 mol−1), 217 (sh), 199 nm (see Electronic Sup-
porting Information, ESI).
Synthesis of 5‑phenylethynyl‑3‑iodo‑1,2,4‑thiadiazole, 4
Under a nitrogen atmosphere, a 50-ml three-necked flask was charged with 
Pd(PPh3)2Cl2 (0.02 g, 0.028 mmol), CuI (0.02 g, 0.1 mmol), 3,5-diiodo-1,2,4-thiadi-
azole (0.3 g, 0.89 mmol), phenylacetylene (0.11 ml, 0.98 mmol), and  Et3N (15 ml). 
The reaction mixture was stirred at 50 °C for 6 h. After cooling to room temperature, 
the resulting mixture was evaporated. The crude material was dissolved in chloro-
form, and the solution was washed with water, dried over anhydrous  MgSO4, and 
evaporated in vacuo. The resulting residue was purified by column chromatography 
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using hexane as the eluent (yield: 57%). M.p.: 66–68 °C. NMR  (CDCl3, r.t.): 1H-
NMR (500  MHz): 7.42 (t, 7.6  Hz, 2H), 7.48 (t, 7.6  Hz, 1H), 7.61 (d, 7.6  Hz, 
2H); 13C-NMR (125 MHz): 77.7 (C7), 105.2 (C8), 117.9 (C3), 120.2 (C9), 128.9 
(C11,13), 131.1 (C12), 132.5 (C10,14), 171.1 (C5) ppm; MS: 311.9  [M]+, 184.9 
 [ICNS]+, 159.0  [PhCCCNS]+, 127.0 m/z  [PhCCCN]+; UV–Vis (λmax, acetonitrile): 
322 (sh), 308, 239 (sh), 227  nm; Raman (neat, characteristic bands): 3068 (vw), 
3053 (vw), 2208 (vs), 1596 (m), 1440 (m), 1347 (w), 1254 (m), 1240 (m), 1107 (w), 
998 (w), 907 (w), 694 (vw)  cm−1. See ESI.
Synthesis of 3,5‑bis(phenylethynyl)‑1,2,4‑thiadiazole, 5
Under a nitrogen atmosphere, a 50-ml three-necked flask was charged with 
Pd(PPh3)2Cl2 (0.02 g, 0.028 mmol), CuI (0.02 g, 0.1 mmol), 3,5-diiodo-1,2,4-thiadi-
azole (0.3 g, 0.89 mmol), phenylacetylene (0.24 ml, 2.22 mmol), and  Et3N (15 ml). 
The reaction mixture was stirred at 70 °C for 10 h. After cooling to room tempera-
ture, the resulting mixture was evaporated. The crude material was dissolved in chlo-
roform, and the solution was washed with water and dried over  MgSO4. After evap-
orating the solvent in vacuo, the residue was purified by column chromatography 
using hexane as the eluent (yield: 64%). M.p.: 115–117 °C. HR-MS: 287.06379 m/z 
([M + 1]+; theoretical value: 287.06429); NMR  (CDCl3, r.t.): 1H-NMR (500 MHz): 
7.38–7.44 (overlapping m’s, 5H), 7.48 (t, 7.6 Hz, 1H), 7.63 (d, 7.6 Hz, 2H), 7.65 (d, 
7.6 Hz, 2H); 13C-NMR (125 MHz): 78.6 (C14), 82.1 (C6), 89.6 (C7), 103.7 (C15), 
120.5 (C16), 121.1 (C8), 128.7 (C10,12), 128.9 (C18,20), 130.0 (C11), 130.9 (C19), 
132.5 (C9,13), 132.7 (C17,21), 157.7 (C3), 169.1 (C5) ppm; UV–Vis (λmax, ace-
tonitrile): 320 (sh), 295, 279, 265 (sh), 228 nm; Raman (neat, characteristic bands): 
3062 (w), 2225 (s), 2206 (vs), 1596 (s), 1454 (w), 1418 (m), 1246 (m), 1195 (m), 
1097 (w), 999 (m)  cm−1 (see ESI).
Single‑crystal XRD of 1 and 4
Single crystals of 1, suitable for XRD analysis, were grown from pentane–chloro-
form (9:1) and ethanol–chloroform (9.5:0.5) solutions by slow evaporation of the 
solvent at room temperature (2 days). Crystals prepared using these two solvent 
mixtures were identical according to XRD. Single crystals of 4 were grown from 
hexane. All crystals suitable for single-crystal X-ray diffractometry were removed 
from a vial and immediately covered with a layer of silicone oil. A single crystal 
was selected, mounted on a glass rod on a copper pin, and placed in the cold  N2 
stream provided by an Oxford Cryosystems cryostream. XRD data collection was 
performed on a Bruker APEX II diffractometer with use of an Incoatec micro-
focus sealed tube of Mo Kα radiation (λ = 0.71073  Å) and a CCD area detec-
tor. Empirical absorption corrections were applied using SADABS or TWINABS 
[12, 13]. The structures were solved with use of the intrinsic phasing option in 
SHELXT and refined by the full-matrix least-squares procedures in SHELXL 
[14–16]. The space group assignments and structural solutions were evaluated 
using PLATON [17, 18]. Non-hydrogen atoms were refined anisotropically. 1 was 
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refined as a 2-component inversion twin (-100 0-10 00-1) using the TWIN option 
in SHELXL and refined with a BASF of 0.27. 4 was refined as a 2-component 
inversion twin (-100 0-10 00-1) using the TWIN option in SHELXL and refined 
with a BASF of 0.03. Electrostatic non-covalent inter-molecular interactions 
[19–22], van der Waals contacts (C–H···X) [23–25], and halide interactions (I···N, 
I···S, I···I) [26–28] were determined by the programs Mercury [29] and Diamond 
[30] using the centroids and planes and other features of these programs. All val-
ues for published compounds were based on a Cambridge Structural Database 
[31] search, and all values for presented and published compounds fall within 
expected ranges. All crystal structures representations were made with the pro-
gram Diamond with all atoms displayed as 30% ellipsoids. Table  1 contains 
Table 1  Crystallographic data and details of measurements for compounds 1 and 4 Mo Kα 
(λ = 0.71073 Å). R1 = Σ/|Fo|–|Fc|/|Σ|Fd; wR2 = [Σw(Fo2 – F22)2/Σw(Fo2)2]1/2
Compound 3,5-Diiodo-1,2,4-thiadiazole (1) 3-Iodo-5-phenylethy-
nyl-1,2,4-thiadiazole (4)
Formula C2I2N2S C10H5IN2S
Fw (g mol−1) 337.90 312.12
a (Å) 4.2178(4) 12.5182(4)
b (Å) 7.6624(6) 43.3045(17)
c (Å) 19.5181(17) 7.8175(4)
α (°) 90 90
β (°) 90 90
γ (°) 90 90
V (Å3) 630.80(10) 4237.8(3)
Z 4 16
Crystal size (mm) 0.03 × 0.02 × 0.02 0.05 × 0.04 × 0.04
Crystal habit Block, colorless Block, colorless
Crystal system Orthorhombic Orthorhombic
Space group P212121 Fdd2
dcalc (Mg m−3) 3.558 1.957
μ  (mm−1) 10.18 3.18
T (K) 100(2) 100(2)
2θ range (°) 2.9–33.2 3.1–33.1
F(000) 592 2368
Tmin, Tmax 0.318, 0.746 0.521, 0.747
Rint 0.053 0.108
No. of measured and observed 
[I > 2 s(I)] reflections
47,194, 1800 128,992, 3899
No. of independent reflections 1801 4069
No. of parameters, restraints 65, 0 128, 1
Δ›max, Δ›min (e Å−3) 0.62, − 1.23 0.84, − 1.30
R1, wR2 (all data) R1 = 0.0134, wR2 = 0.0335 R1 = 0.0268, wR2 = 0.0605
R1, wR2 (> 2σ) R1 = 0.0134, wR2 = 0.0335 R1 = 0.0244, wR2 = 0.0592
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crystallographic data and details of measurements and refinement for compounds 
1 and 4.
Quantum chemical calculations
Quantum chemical calculations were performed using the Gaussian-09 quantum 
chemistry package [32]. Equilibrium structures of molecules were computed using 
the B3LYP method and aug-cc-pVTZ basis set on C, N, and S atoms and aug-cc-
pVTZ-pp basis set on I atoms [33]. Vibrational and electronic spectra were then cal-
culated using these minimum energy structures. For characterization of the normal 
vibrational modes of 1, the B3LYP harmonic force field was scaled and the scaled 
force field was used for the determination of the total energy distribution (TED), 
which provides a measure of the internal coordinate contributions [34, 35].
Results and discussion
Synthesis and structure of 1
Based on the perusal of the relevant literature, 3,5-diamino-1,2,4-thiadiazole (3) 
[11] (ESI) seemed to be a promising precursor for the synthesis of 1 and 2. Aqueous 
phase diazotization reactions, however, led to no avail due to the insolubility of 3 in 
aqueous acidic media, namely aq. HCl, aq. HBr, aq. HI, aq.  H2SO4, and aq. acetic 
acid. Non-aqueous diazotization of 3 using tert-butyl nitrite and CuI was successful 
for producing 1 (Scheme 1). 1 was unambiguously identified and characterized by 
NMR, IR, Raman, mass, and UV–Vis spectroscopies, and the solid phase structure 
Scheme 1  Synthesis of 1, 4, and 5 
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was determined by single-crystal X-ray diffraction. We note that it was not possi-
ble to synthesize the dibromo derivative, 2, using analogous method and CuBr or 
 CuBr2. 1 is slightly sensitive to prolonged daylight but stable in the dark. It absorbs 
in the near UV at 237 and 261 nm corresponding to excitations from aʺ iodine lone 
pair orbitals to thiadiazole vacant π orbitals (n–π* transitions, see Fig. 1).
Fig. 1  UV spectrum of 1 in acetonitrile. Blue bars indicate theoretical excitation energies calculated at 
the TD-B3LYP/aug-cc-pVTZ-pp level (calculated excitation energies are shifted by −10 nm for compari-
son, see Table S1)
Fig. 2  Structure and crystal packing interactions of 1. All atoms are shown as 30% shaded ellipsoids
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The crystal structure of 1 is shown in Fig.  2 with geometric parameters listed 
in Table  2. Compound 1 crystallizes in the orthorhombic space group P212121. 1 
has a planar structure  (Cs symmetry) and thiadiazole molecules are arranged in zig-
zag stripes in the solid phase forming weak I···N contacts. I···N distances, namely 
2.995(4) and 3.196(3) Å, are slightly below the sum of van der Waals radii of atoms 
(3.53 Å), but I···S and I···I distances are about the same, 3.7621(1) versus 3.78 Å 
and 3.9774(4) versus 3.96 Å, respectively (see Tables S2 and S3, ESI).
The IR and Raman spectra of 1 are shown in Fig.  3, with experimental and 
computed vibrational frequencies and intensities listed in Table  3. The 15 nor-
mal vibrational modes of 1 transform into 11a′ + 4a″ vibrational species, all IR 
and Raman active. All of these fundamentals were identified in IR or Raman 
Table 2  Geometric parameters 
for 3,5-diiodo-1,2,4-thiadiazole 
(1)
Bond lengths (Å) Bond angles (°)
I6–C3 2.080 (4) N2–S1–C5 92.69 (18)
I7–C5 2.072 (4) C3–N2–S1 107.3 (3)
S1–N2 1.663 (4) C5–N4–C3 108.1 (3)
S1–C5 1.711 (4) N2–C3–N4 119.5 (3)
N2–C3 1.317 (5) N2–C3–I6 123.2 (3)
N4–C5 1.313 (5) N4–C3–I6 117.3 (3)
N4–C3 1.383 (6) N4–C5–S1 112.4 (3)
N4–C5–I7 122.2 (3)
S1–C5–I7 125.4 (2)
Fig. 3  IR (KBr pellet) and Raman (neat) spectra of 1. See Table 3. Note that band broadening occurs in 
IR due to relatively large crystallite size even after 30 min ball milling
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spectra. The calculated frequencies and relative IR and Raman intensities 
(albeit computed for an isolated molecule) are in good agreement with experi-
ment and support the band assignments. All of the IR/Raman bands observed in 
the 1600–400 cm−1 region can be assigned to the thiadiazole moiety. The most 
intensive thus the most characteristic fingerprints of the ring are the IR bands at 
1396 and 1162 cm−1 and the Raman band at 1297 cm−1 corresponding to C=N 
and C–N stretches (see Table 3). Vibrational bands which originate from the C–I 
stretches and in- and out-of-plane deformations are observed below 400 cm−1; the 
most intensive at 208 cm−1 is assigned to C–I stretch.
Table 3  Experimental and calculated vibrational wavenumbers  (cm−1) of 3,5-diiodo-1,2,4-thiadiazole (1)
st stretching, rb in-plane ring bend, rt out-of-plane ring torsion, b in-plane bend, ob out-of-plane bend, 
n.o. not observed
a Anharmonic vibrational frequencies and vibrational symmetry. Values in parenthesis are obtained by 
correcting CCSD (T) harmonic vibrational wavenumbers with B3LYP anharmonic corrections. Molecu-
lar symmetry is  Cs. Isotopes: 127I, 32S, 12C, 14N. Calculated using aug-cc-pVTZ-pp basis set
b Anharmonic IR intensities in km/mol
c Relative Raman intensities, calculated using the B3LYP harmonic force field and method described in 
our previous paper [36]. The relative Raman intensity of ν10 was selected to be 100
d Characterization of the fundamentals; TED (total energy distribution). Only contributions above 5% are 
given. The pairs of two C=N st, two C–I st, two rb, two rt, two C–I b, and two C–I ob are strongly mixed, 
therefore their sum contribution is provided in the table
Experimental Calculated Assignment and TED %d
IR Raman solid B3LYP/aug-cc-pVTZ-pp
KBr pellet Freq.a IR int.b Raman Int.c
1396 1399 1425 (1409) a′ 175.7 1.7 ν1 97% C=N st
1332 2·ν12 overtone?
1322 2·ν7 overtone?
1297 1298 1318 (1305) a′ 17.1 21.4 ν2 96% C=N st
1162 1160 1140 (1147) a′ 280.7 12.3 ν3 80% C–N st, 8% rb, 7% C–I st
994 995 973 (992) a′ 65.1 11.3 ν4 53% rb, 18% S-C st, 13% C–I st
874 871 860 (861) a′ 62.2 32.8 ν5 53% rb, 18% S-C st, 12% C–I st
762 762 740 (760) a′ 3.3 16.2 ν6 85% S–N st, 8% S-C st
667 667 669 (654) a″ 1.2 0.2 ν12 74% rt, 25% C–I ob
660 661 653 (657) a′ 3.8 39.8 ν7 43% S-C st, 44% rb
523 527 (517) a″ 2.3 0.1 ν13 68% rt, 29% C–I ob
353 348 (353) a′ 1.8 2.8 ν8 54% C–I st, 18% rb, 27% C–I b
343 ν10 + ν15 combination band?
257 248 (249) a′ 2.1 31.7 ν9 55% C–I b, 32% C–I st
252 223 (220) a″ 1.5 5.7 ν14 66% C–I ob, 31% rt
208 200 (204) a′ 0.4 100 ν10 61% C–I st, 15% C–I b, 12% rb
133 118 (116) a″ 1.0 16.6 ν15 78% C–I ob, 21% rt
110 91 (91) a′ 0.3 131 ν11 86% C–I b
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Cross‑coupling reactions of 1
1 is expected to be an important building block for the construction of larger bio-
logically active thiadiazole derivatives; therefore, it is a logical step to test its perfor-
mance in cross-coupling reactions. Sonogashira-type cross-coupling reactions have 
been selected first and phenylacetylene as the model reagent. Cross-coupling in tri-
ethylamine solvent has led smoothly and selectively to the mono-substituted product 
at position five (C5) 4 (Scheme 1). This selectivity can be explained by the lower 
electron density and thus higher reactivity with nucleophiles at C5 of the heterocy-
clic ring, relative to C3 [6]. A plausible mechanism is provided in Scheme S1, ESI. 
Slightly increasing temperature and reaction time and doubling the phenylacetylene 
content compared to 1 have produced the di-substituted derivative 5. Therefore, the 
synthetic protocol, in general, is appropriate to attach two substituents on the thia-
diazole ring as desired in two steps by selecting the order of reagents and reaction 
conditions. We note that addition of one or two equivalent of  PPh3 to the catalyst has 
not affected the yield of products, but caused difficulties in column chromatographic 
separation; therefore, application of  PPh3 has been rejected in this work. Mass, 
vibrational, and NMR spectroscopic data have unambiguously identified the prod-
ucts. Ethynyl groups have provided strong and characteristic bands in the Raman 
spectra (Figure S8, ESI). The comparison of the measured and calculated NMR data 
unambiguously ruled out substitution at position C3 for the mono-coupled prod-
uct (Figure S11, ESI). The structure of 4 has also been confirmed by single-crys-
tal X-ray diffraction. Crystallographic data and selected geometric parameters are 
listed in Tables 1 and S4, respectively. Compound 4 crystallizes in the orthorhombic 
space group Fdd2. 4 has a planar structure where the phenyl and thiadiazole rings 
are coplanar with each other (see Fig. 4). Molecules are packed in layers in the solid 
Fig. 4  Structure, crystal packing, and I∙∙∙N interactions of 4. All atoms are shown as 30% shaded ellip-
soids
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phase forming weak I···N inter-molecular contacts (I···N distances are slightly below 
the sum of van der Waals radii of atoms, but I···S and I···I distances are above typical 
I···S and I···I ranges, see Tables S3, S4 and S5, ESI).
Molecules 4 and 5 absorb in the near UV at all wavelengths below 340  nm 
(Fig. 5) due to a large number of overlapping UV bands emerging from the delocal-
ized π-system of the planar molecular structures (confirmed by X-ray diffraction, 
above, and B3LYP computations, ESI).
Conclusion
1 can be synthesized from its diamino derivative using non-aqueous diazotization 
reactions and has been proven to be an effective reagent in Sonogashira-type cross-
coupling reactions. In these reactions, the two iodine atoms of 1 have been replaced 
step by step, first at the C5 position and then at C3, what provides the possibility for 
selectively attaching different substituents at the C3 and C5 positions of the thiadia-
zole ring. 1 is thus expected to be an important building block for producing biologi-
cally active 1,2,4-thiadiazole derivatives. 1 and its cross-coupled products have been 
characterized by spectroscopic and diffraction techniques. We note that we have 
synthesized several phenyl, ethynylferrocenyl, and erlotinib derivatives of 1 based 
on synthetic methods published in this work and initiated the investigation of their 
antiproliferative effect against tumorous glioma U87 and carcinoma A431 human 
cell lines with colleagues at the Eötvös Loránd University. According to our prelimi-
nary data, both 4 and 5 were active against carcinoma A431 cell lines and 5 was also 
active against glioma U87 cell growth.
Fig. 5  UV spectra of 4 and 5 in acetonitrile
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Supplementary material
Data including NMR, mass, IR/Raman, UV, and crystal structure related to this arti-
cle are available on the Journal’s website. Crystallographic data (excluding struc-
ture factors) for the structures in this paper have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication nos. CCDC 1917563 
and 1917564 for 1 and 4, respectively.
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